These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17289744)

  • 21. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
    Gomberg-Maitland M; Wenger NK; Feyzi J; Lengyel M; Volgman AS; Petersen P; Frison L; Halperin JL
    Eur Heart J; 2006 Aug; 27(16):1947-53. PubMed ID: 16774980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Warfarin therapy and systolic hypertension in men with atrial fibrillation.
    Krishnan S; Chawla N; Ezekowitz MD; Peixoto AJ
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1592-9. PubMed ID: 16364831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V.
    Hylek EM; Frison L; Henault LE; Cupples A
    Stroke; 2008 Nov; 39(11):3009-14. PubMed ID: 18703812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S; Diamond GA; Weintraub WS
    J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
    Cleland JG; Shelton R; Nikitin N; Ford S; Frison L; Grind M
    Eur J Heart Fail; 2007; 9(6-7):730-9. PubMed ID: 17360232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-intensity anticoagulation for stroke prevention in elderly patients with atrial fibrillation: efficacy and safety in actual clinical practice.
    Ono A; Fujita T
    J Clin Neurosci; 2005 Nov; 12(8):891-4. PubMed ID: 16271478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
    Olsson SB;
    Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
    Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
    J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study).
    Friberg L; Hammar N; Ringh M; Pettersson H; Rosenqvist M
    Eur Heart J; 2006 Aug; 27(16):1954-64. PubMed ID: 16847008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
    Reiffel JA
    Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.
    Vemulapalli S; Hellkamp AS; Jones WS; Piccini JP; Mahaffey KW; Becker RC; Hankey GJ; Berkowitz SD; Nessel CC; Breithardt G; Singer DE; Fox KA; Patel MR
    Am Heart J; 2016 Aug; 178():74-84. PubMed ID: 27502854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
    Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
    Thromb Haemost; 2009 May; 101(5):938-42. PubMed ID: 19404548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
    Berry C; Norrie J; McMurray JJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW
    Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
    [No Abstract]   [Full Text] [Related]  

  • 39. Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics.
    Ezekowitz MD
    Am Heart Hosp J; 2004; 2(4 Suppl 1):31-5. PubMed ID: 15539973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.